Trial · NCT00003042

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

NCT00003042, Phase 2, Completed, City of Hope Medical Center; results first posted 2021-04-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer. Trials, record NCT00003042. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00003042

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
NCT number: NCT00003042
Status: Completed
Phases: Phase 2
Enrollment: 41 participants, actual
Lead sponsor: City of Hope Medical Center
Conditions: Breast Cancer
Interventions: filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, melphalan, mesna, paclitaxel, tamoxifen citrate, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation
First posted: 2003-01-27
Last updated: 2026-02-20
Results first posted: 2021-04-08

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Three-year Relapse-free Survival	From date of mastectomy until date of relapse or death from any cause, 3 years post mastectomy.	Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment.
Primary	Five-year Overall Survival	From date of mastectomy until date of death, 5 years post mastectomy.	Estimated using the product-limit method of Kaplan and Meier. Endpoint is defined as death due to any cause.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Three-year Relapse-free Survival	From date of mastectomy until date of relapse or death from any cause, 3 years post mastectomy.		percentage of participants	NUMBER
PRIMARY	Five-year Overall Survival	From date of mastectomy until date of death, 5 years post mastectomy.		percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Three-year Relapse-free Survival	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	61.5	95% Confidence Interval 30.8 to 81.8	percentage of participants
Three-year Relapse-free Survival	High-dose Chemo With Rescue	77.8	95% Confidence Interval 57.1 to 89.3	percentage of participants
Five-year Overall Survival	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	69.2	95% Confidence Interval 37.3 to 87.2	percentage of participants
Five-year Overall Survival	High-dose Chemo With Rescue	70.4	95% Confidence Interval 49.4 to 83.9	percentage of participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	14
Overall Study	STARTED	High-dose Chemo With Rescue	27
Overall Study	COMPLETED	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	14
Overall Study	COMPLETED	High-dose Chemo With Rescue	27
Overall Study	NOT COMPLETED	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	0
Overall Study	NOT COMPLETED	High-dose Chemo With Rescue	0

Source ClinicalTrials.gov

Adverse events348

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Cerebellar	Nervous system disorders	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	4	14	7
other	Cerebellar	Nervous system disorders	High-dose Chemo With Rescue	10	27	19
other	Dysrhythmias	Cardiac disorders	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	4	14	8
other	Dysrhythmias	Cardiac disorders	High-dose Chemo With Rescue	9	27	15
other	Fluid Retention	Renal and urinary disorders	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	5	14	24
other	Fluid Retention	Renal and urinary disorders	High-dose Chemo With Rescue	10	27	26
other	Haematemesis	Gastrointestinal disorders	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	0	14	0
other	Haematemesis	Gastrointestinal disorders	High-dose Chemo With Rescue	1	27	1
other	Infection	Infections and infestations	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	6	14	25
other	Infection	Infections and infestations	High-dose Chemo With Rescue	11	27	27

1 to 10 of 348Source ClinicalTrials.gov

See all 348 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	10	14
Total, all-cause mortality	High-dose Chemo With Rescue	14	27
Total, other adverse events	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	13	14
Total, other adverse events	High-dose Chemo With Rescue	23	27
Total, serious adverse events	Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	0	14
Total, serious adverse events	High-dose Chemo With Rescue	2	27

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA033572	Cancer Center Support Grant	CARPTEN, JOHN D.	BECKMAN RESEARCH INSTITUTE/CITY OF HOPE	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue vs High-dose Chemo With Rescue: deaths from any cause	Trial comparisons
Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue vs High-dose Chemo With Rescue: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00003042

GET https://conductscience.org/api/trials/v1/NCT00003042/events?page=2

API reference For AI assistants